Literature DB >> 6461238

Reversal of left ventricular hypertrophy in hypertensive patients treated with methyldopa. Lack of association with blood pressure control.

F M Fouad, Y Nakashima, R C Tarazi, E E Salcedo.   

Abstract

Ten patients with essential hypertension and left ventricular hypertrophy were treated with relatively small doses of methyldopa (500 to 750 mg/day) added to long-term diuretic therapy. Sequential M mode echocardiography showed significant reduction in left ventricular mass 36 weeks after addition of methyldopa in four patients (359 +/- 77 [standard error of the mean] to 235 +/- 63 g) although blood pressure was not significantly altered by the added treatment. In three of these patients, reduction of left ventricular mass was observed as early as 12 weeks of treatment (384 to 262 g). Neither left ventricular mass to left ventricular volume ratio nor fractional shortening was significantly altered by reduction in left ventricular mass (3.21 +/- 0.26 to 2.74 +/- 0.24 and 0.42 +/- 0.03 to 0.44 +/- 0.02, respectively). There was no apparent relation in these patients between changes in blood pressure and changes in left ventricular mass. Thus, reversal of cardiac hypertrophy with antihypertensive treatment is possible in human beings; however, it seems to depend on other factors besides blood pressure control.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6461238     DOI: 10.1016/0002-9149(82)91961-0

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  25 in total

1.  Regression of left ventricular hypertrophy in "previously untreated" hypertensive blacks after 6 months of blood pressure reduction with alpha- and beta-adrenergic blockade and thiazide therapy.

Authors:  E Foster; J F Plehn; S A Bernard; N J Battinelli; M Huntington-Coats; C S Apstein
Journal:  Cardiovasc Drugs Ther       Date:  1992-04       Impact factor: 3.727

Review 2.  Therapeutic effect on left ventricular hypertrophy by different antihypertensive drugs.

Authors:  W Motz; B E Strauer
Journal:  Clin Investig       Date:  1992

Review 3.  Hypertension.

Authors:  G W Ching; D G Beevers
Journal:  Postgrad Med J       Date:  1991-03       Impact factor: 2.401

Review 4.  Reserpine: a relic from the past or a neglected drug of the present for achieving cost containment in treating hypertension?

Authors:  G J Magarian
Journal:  J Gen Intern Med       Date:  1991 Nov-Dec       Impact factor: 5.128

Review 5.  Regression of increased left ventricular mass by antihypertensives.

Authors:  C J Lavie; H O Ventura; F H Messerli
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

6.  Regression of left ventricular hypertrophy by acebutolol and nifedipine.

Authors:  I W Franz; U Tönnesmann; U Behr; R Ketelhut
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

7.  Comparison between the effects of urapidil and methyldopa on left ventricular hypertrophy and haemodynamics in humans.

Authors:  C A Feldstein; A O Olivieri; R P Sabarís
Journal:  Drugs       Date:  1988       Impact factor: 9.546

8.  Treatment of essential hypertension: changes in blood pressure, echocardiography and electrocardiography on three therapeutic regimes.

Authors:  G I Russell; J E Pohl; J Baldwin; R F Bing; A M Heagerty; H Thurston; J D Swales
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 9.  Effects of different antihypertensive drugs on left ventricular function.

Authors:  R Oliveri
Journal:  Drugs       Date:  1988       Impact factor: 9.546

10.  Regression of left ventricular hypertrophy during combined atenolol and nifedipine treatment.

Authors:  I W Franz; U Tönnesmann; U Behr; R Ketelhut
Journal:  Drugs       Date:  1988       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.